SURVYR

ERAS

ERAS
$15.12
−$0.10 (0.66%)Oct 28 close
US Equities CompareTechnicals
1M3M6M1Y2Y
-8%+204%+416%+628%+840%Oct 2025Oct 2026Apr 202652w high $22.4752w low $2.20
ERASSPY
Wall St. Highest PT $28.51 (+88.6%) Wall St. Avg PT $23.37 (+54.6%)
$2$9$16$23$29POC $15Hi $29Avg $23
Underwater Drawdown %Max DD -59.5%Current -32.7%
0.0%-59.5%
Relative Strength vs SPY+518.7% vs SPYOutperforming
+962%0%-962%
1W
+$0.63 (4.35%)
1M
+$0.99 (7.01%)
3M
−$2.60 (14.67%)
6M
+$6.01 (65.97%)
YTD
+$11.40 (306.45%)
1Y
+$12.68 (519.67%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street & Morningstar coverage
Wall Street consensusNo covering analysts on file for ERAS
Analyst price targetsNo target range on file
Morningstar star ratingNot rated
Checked Wall Street & Morningstar feeds · All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

52-week range$2.20 – $22.47

What they do

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for ERAS yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

ERAS earningsNext report in 14 days
Next report · quarter Sep 2026
Wed Nov 11, 2026Time not confirmed
EPS consensus-$0.13
Revenue consensus–
Last 4 quarters · EPS vs estimate
Aug 11, 2026-$0.14est -$0.11−25.3%Below estimates
May 11, 2026-$0.60est -$0.23−166.0%Below estimates
Mar 12, 2026-$0.10est -$0.11+6.0%Above estimates
Nov 12, 2025-$0.11est -$0.11−4.5%In line with estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 18:27:22 ET
24-1125-0325-0525-0825-1126-0326-0526-08-0.600.00
EstimateActual (beat)Actual (miss)

News & catalysts

More news
No recent headlines.
Insider trades
None
None · None
Sell
–

Stats refreshed 2026-10-21 18:27:22 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026